NkartaNKTX
NKTX
About: Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Employees: 157
0
Funds holding %
of 7,302 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
27% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 30
6% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 18
0% more funds holding
Funds holding: 112 [Q4 2024] → 112 (+0) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
1.37% less ownership
Funds ownership: 88.09% [Q4 2024] → 86.72% (-1.37%) [Q1 2025]
27% less capital invested
Capital invested by funds: $155M [Q4 2024] → $113M (-$41.5M) [Q1 2025]
34% less call options, than puts
Call options by funds: $38K | Put options by funds: $58K
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
465%
upside
Avg. target
$14
691%
upside
High target
$18
917%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Mizuho Salim Syed | 691%upside $14 | Outperform Maintained | 10 Jun 2025 |
Needham Gil Blum | 465%upside $10 | Buy Maintained | 15 May 2025 |
Stifel Stephen Willey | 691%upside $14 | Buy Maintained | 27 Mar 2025 |
HC Wainwright & Co. Emily Bodnar | 917%upside $18 | Buy Reiterated | 27 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pursue other opportunities in the oncology space.
Positive
Zacks Investment Research
1 month ago
Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade
Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Negative
Benzinga
1 month ago
Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space
Nkarta Inc. NKTX on Wednesday reported a first-quarter loss of 43 cents per share, beating the consensus loss of 44 cents.
Neutral
GlobeNewsWire
1 month ago
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eligible patients Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $351.9 million on March 31, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the first quarter and year ended March 31, 2025.
Positive
Zacks Investment Research
2 months ago
Nkarta (NKTX) Upgraded to Buy: Here's Why
Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
2 months ago
Nkarta to Participate in an April Investor Conference
SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
Positive
Seeking Alpha
2 months ago
Nkarta: Grinding Lower, Trying To Find Support
Nkarta, Inc. has provided significant pipeline updates, showcasing promising advancements in their innovative cell therapy treatments. A financial overview highlights a robust balance sheet, with sufficient cash reserves to support ongoing research and development activities. Strengths include cutting-edge technology and strategic partnerships, while risks involve clinical trial uncertainties and regulatory hurdles.
Positive
Seeking Alpha
2 months ago
Nkarta: Betting On The Turnaround
Nkarta's NKX019 shows promise in treating autoimmune diseases, despite a 70% stock drop; strategic restructuring extends financial runway to 2029. Q4 and full-year 2024 earnings reveal significant R&D expenses and a net loss, but a strong cash position of $380.5M. Upcoming clinical data from Ntrust-1 and Ntrust-2 trials are key catalysts; positive results could validate NKX019 and attract investor attention.
Positive
Benzinga
2 months ago
Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?
Nkarta, Inc. NKTX reported a fourth-quarter earnings report on Wednesday with a loss of 35 cents per share, beating the consensus of a loss of 41 cents.
Neutral
GlobeNewsWire
2 months ago
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestones Cash balance of $380.5 million on December 31, 2024, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the fourth quarter and year ended December 31, 2024.
Charts implemented using Lightweight Charts™